Author:
Fedorov Vladimir N.,Smirnov Nikolai A.,Vdovichenko Vladimir P.,Fedorova Tatyana B.,Kerbenev Edgar E.,Petrovsky Aleksei K.
Abstract
Introduction: Tuberculosis is a widely spread infection. While treating patients for it, they are given simultaneously and for a long period 5-6 antibacterial drugs, which are, as a rule, bad for the liver. It quite often (up to 20%) causes drug-induced hepatitis. As experimental means of protecting the liver, the following peptides are suggested: chorionic gonadotropin, a recombinant drug of luteinizing hormone – luveris, and oligopeptide drugs: semax and selank.
Materials and Methods: The research was conducted on 104 outbred white male rats weighing 170-220 g. Each group included at least 10 animals. Drug-induced hepatitis was simulated through the combined 21-day administration of isoniazid, rifamycin, and ethanol. Chorionic gonadotropin, luveris, semax and selank, as well as a comparison drug mexidol, were administered once a day during the experiment. Healthy control animals and rats with drug-induced hepatitis were used as comparison groups. For evaluation of the efficiency of administered drugs, the obtained biochemical and histomorphological research data was used.
Results and Discussion: During the experiment, chorionic gonadotropin (ChG), semax and selank showed a greater therapeutic activity than mexidol and luveris. Only in the case of administering ChG, selank and semax, there was parallelism between the restoration of biochemical parameters of blood and histomorphological parameters of the liver. Administering both selank and ChG was also characterized by more active regenerative processes.
Conclusion: Administering ChG, selank and semax to patients with tuberculosis would significantly reduce the number and severity of hepatotoxic reactions.
Subject
Pharmacology (medical),Pharmacology
Reference34 articles.
1. Hepatoprotective therapy of liver diseases in children.;Babayan;Attending Physician [Lechashchii Doktor],2013
2. Possibility of treating drug-induced liver lesions when having to take hepatoxins.;Bueverov;Attending Physician [Lechashchii Doktor],2009
3. Pharmacogenetic Study of Drug-Metabolising Enzyme Polymorphisms on the Risk of Anti-Tuberculosis Drug-Induced Liver Injury: A Meta-Analysis
4. Silymarin as a New Hepatoprotective Agent in Experimental Cholestasis: New Possibilities for an Ancient Medication
5. Multiple (mixed) tuberculosis infection.;Drobin;Tuberculosis and Lung Diseases [Tuberkulez i Bolezni Legkikh],2014